GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Beyond Amyloid Plaques: How Brainshuttle Drugs, Primary Care Blood Tests, and Cellular Science Are Rewriting Alzheimer’s Trials in Late 2026
Explore the latest November 2026 Alzheimer's clinical trial updates. Learn how Roche's Brainshuttle technology crosses the blood-brain barrier, how FDA-cleared blood tests simplify diagnosis in primary care, and what five-year data reveals about slowing cognitive decline.